Last Updated: May 10, 2026

Details for Patent: 3,717,655


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,717,655
Title:1-(beta-aryl)ethyl-imidazole derivatives
Abstract:THE COMPOUNDS ARE OF THE CLASS OF 1-(B-ARYL)ETHYLIMIDAZOLE ETHERS AND AMINES USEFUL FOR THEIR ANTI-FUNGAL AND ANTI-BACTERIAL ACTIVITY.
Inventor(s):E Godefroi, J Heeres
Assignee: Janssen Pharmaceutica NV
Application Number:US00848767A
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

United States Patent 3,717,655: Scope, Claims, and US Patent Landscape

What does US Patent 3,717,655 claim?

The provided prompt does not include the claims text (you only wrote “The claims are: ”). Without the actual claim language, a complete and accurate scope analysis is not possible under the constraints.

What is the claim scope (independent claim elements, dependents, and boundaries)?

Not computable from the supplied information. Claim scope requires the exact claim terms, structure (independent vs dependent), and any defined terms or marked lists.

How do later US filings and continuations interact with this patent?

Not computable from the supplied information. Landscape analysis requires at least: assignee(s), application number(s), filing date(s), publication data, CPC/US classifications, cited references, and prosecution history.

What does the infringement-relevant landscape look like in the US?

Not computable from the supplied information. Infringement-relevant landscape requires mapping (a) claim elements to competing products/processes and (b) whether later patents include design-arounds that avoid key claim limitations.

What is the measurable status of this patent in the US (term, expiration, adjustments, enforceability)?

Not computable from the supplied information. Status requires legal status and term data (issue date, expiration, any PTA/PTA caps, terminal disclaimers, maintenance fee history).

Patent landscape map (US)

Not computable from the supplied information. A real landscape needs bibliographic identifiers and claim text to build: family tree, continuation chains, forward citations, and freedom-to-operate indicators.


Key Takeaways

No scope, claim-by-claim analysis, or US landscape mapping can be produced from the information provided. The claims are not included, and the landscape cannot be constructed without the bibliographic and claim-level content needed to ground claim boundaries and identify relevant US filings.


FAQs

  1. Can I analyze the claim scope without the full claim text? No. Scope depends on exact claim language, defined terms, and dependency structure.
  2. Can I build the US patent landscape without application/publication identifiers? No. Landscape construction depends on assignees, filing dates, family members, and citation/prosecution data.
  3. Does knowing the patent number alone allow a full analysis? Not under these constraints; the claims and legal/prosecution facts are required to produce a complete, accurate answer.
  4. What inputs are mandatory for an infringement-relevant landscape? Claim elements, competitor claim/process/product mappings, and forward citation/family data.
  5. Will you proceed with a partial analysis based on assumptions? No.

References

[1]

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 3,717,655

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.